Could anti-inflammatory actions of catecholamines explain the possible beneficial effects of supranormal oxygen delivery in critically ill surgical patients?

Intensive Care Medicine

Volumn 26, Issue 3, 2000, Pages 299-304

  Uusaro, A ^a   Russell, J A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Catecholamines; Critical care; Cytokines; Oxygen consumption; Oxygen delivery; Randomized controlled trials

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; ADRENERGIC RECEPTOR; AMRINONE; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYCLIC AMP; CYTOKINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPEXAMINE; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; ISOPRENALINE; NORADRENALIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; HIGH RISK PATIENT; HUMAN; HYPOXIA; IMMUNOMODULATION; INTENSIVE CARE; MORTALITY; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SURGICAL PATIENT;

EID: 0034115618     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340051153     Document Type: Review

References (41)

1. 1. Russell JA, Phang PT (1994) The oxygen delivery consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med 149: 533-537
2. 2. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS (1988) Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94: 1176-1186
3. 3. Yu M, Burchell S, Hasaniya NW, Takanishi DM, Myers SA, Takiguchi SA (1998) Relationship of mortality to increasing oxygen delivery in patients ≥ 50 years of age: a prospective, randomized trial Crit Care Med 26: 1011-1019
4. 4. Boyd O, Grounds RM, Bennett ED (1993) A randomized clinical trial of the effect deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 270: 2699-2707
5. 5. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330: 1717-1722
6. 6. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 333: 1025-1032
7. 7. Tuchschmidt J, Fried J, Astiz M, Rackow E (1992) Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 102: 216-220
8. 8. Bishop MH, Shoemaker WC, Appel PL, Meade P, Ordog GJ, Wasserberger J, Wo CJ, Rimle DA, Kram HB, Umali R (1995) Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma. J Trauma 38: 780-787
9. 9. Fleming A, Bishop M, Shoemaker W, Appel P, Sufficool W, Kuvhenguwha A, Kennedy F (1992) Prospective trial of supranormal values as goals of resuscitation in severe trauma. Arch Surg 127: 1175-1181
10. 10. Gutierrez G, Palizas F, Doglio G, Wainsztein N, Gallesio A, Pacin J, Dubin A, Schiavi E, Jorge M, Pusajo J, Klein F, San Roman E, Dorfman B, Shottlender J, Giniger R (1992) Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 339: 195-199
11. 11. Yu M, Levy MM, Smith P, Takiguchi SA, Miyasaki A, Myers SA (1993) Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med 21: 830-838
12. 12. Ronco JJ, Fenwick JC, Tweeddale MG, Wiggs BR, Phang PT, Cooper DJ, Cunningham KF, Russell JA, Walley KR (1993) Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA 270: 1724-1730
13. 13. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A (1981) A method of assessing the quality of a randomized control trial. Control Clin Trials 2: 31-49
14. 14. Heyland DK, Cook DJ, King D, Kernerman P, Brun-Buisson C (1996) Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Crit Care Med 24: 517-524
15. 15. Chittock D, Baigorri F, Russell JA (1996) Randomized controlled trials (RCT's) of increased oxygen delivery (DO2) in critical illness: a meta-analysis. Am J Resp Crit Care Med 153: A466
16. 16. Consensus Conference (1996) Tissue hypoxia. How to detect, how to correct, how to prevent. Am J Respir Crit Care Med 154: 1573-1578
17. 17. Russell JA (1993) Quantitative assessment of randomized controlled trials of increased oxygen delivery in critically ill adults. Am Rev Respir Dis 147: A616
18. 18. Cruickshank AM, Fraser WD, Burns HJG, van Damme J, Shenkin A (1990) Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 79: 161-165
19. 19. Tang GJ, Kuo CD, Yen TC, Kuo HS, Yien HW, Lee TY (1996) Perioperative plasma concentrations of tumor necrosis factor-alpha and interleukin-6 in infected patients. Crit Care Med 24: 423-428
20. 20. Kragsbjerg P, Holmberg H, Vikerfors T (1995) Serum concentrations of interleukin-6, tumour necrosis factor-alpha, and C-reactive protein in patients undergoing major operations. Eur J Surg 161: 17-22
21. 21. Tighe D, Moss R, Heywood G, Al-Saady N, Webb A, Bennett D (1995) Goal-directed therapy with dopexamine, dobutamine and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Crit Care Med 23: 1997-2007
22. 22. Berendes E, Mollhoff T, van Aken H, Schmidt C, Erren M, Deng MC, Weyand M, Loick HM (1997) Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 84: 950-957
23. 23. Marik PE, Mohedin M (1994) The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 272: 1354-1357
24. 24. Uusaro A, Ruokonen E, Takala J (1995) Gastric mucosal pH does not reflect changes in splanchnic blood flow after cardiac surgery. Br J Anaesth 74: 149-154
25. 25. Bone RC (1996) Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125: 680-687
26. 26. Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565-575
27. 27. Donnelly SC, Strieter RM, Reid P, Kunkel SL, Burdick MD, Armstrong I, Mackenzie A, Haslett C (1996) The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluid of patients with the adult respiratory distress syndrome. Ann Intern Med 125: 191-196
28. 28. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1100
29. 29. McCarthy Pastores S, Hasko G, Vizi ES, Kvetan V (1996) Cytokine production and its manipulation by vasoactive drugs. New Horiz 4: 252-264
30. 30. Zabel P, Wolter DT, Schonharting MM, Schade UF (1989) Oxpentifylline in endotoxemia. Lancet ii: 1474-1478
31. 31. Schade UF (1990) Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171-181
32. 32. Barton MH, Moore JN (1994) Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 44: 216-220
33. 33. Standiford TJ, Streiter RM, Lukacs NW (1995) Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 155: 2222-2229
34. 34. Giroir BP, Beutler B (1992) Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock 36: 200-207
35. 35. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ (1995) Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 268: R896-R901
36. 36. Monastra G, Secchi EF (1993) βb-adrenergic receptors mediate in vivo the adrenaline inhibition of polysaccharide-induced tumor necrosis factor release. Immunol Lett 38: 127-130
37. 37. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF (1996) Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97: 713-719
38. 38. Severn A, Rapson NT, Hunter CA (1992) Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 148: 3441-3445
39. 39. Van der Poll, Jansen J, Endert E, Sauerwein HP, van Deventer SJ (1994) Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-6 production in human whole blood. Infect Immun 62: 2046-2050
40. 40. Ritchie PK, Ashby M, Knight HH, Judd AM (1996) Dopamine increases interleukin 6 release and inhibits tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro. Eur J Endocrinol 134: 610-616
41. 41. Hasko G, Szabo C, Merkel K, Bencsics A, Zingarelli B, Kvetan V, Vizi ES (1996) Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice. Immunol Lett 49(3): 143-147